[5-alpha reductase inhibitors plus alpha blockers. A combination therapy keeps a common disease checked].
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D000367:Age Factors; D000368:Aged; D017292:Doxazosin / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D018120:Finasteride / Q000008:administration & dosage* / Q000627:therapeutic use; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000453:epidemiology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D010919:Placebos; D018120:Finasteride; D017292:Doxazosin